Cargando…
Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
OBJECTIVES: The Oxford–AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate the funding for the...
Autores principales: | Cross, Samuel, Rho, Yeanuk, Reddy, Henna, Pepperrell, Toby, Rodgers, Florence, Osborne, Rhiannon, Eni-Olotu, Ayolola, Banerjee, Rishi, Wimmer, Sabrina, Keestra, Sarai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704023/ https://www.ncbi.nlm.nih.gov/pubmed/34937701 http://dx.doi.org/10.1136/bmjgh-2021-007321 |
Ejemplares similares
-
Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021) -
Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021) -
Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
por: Østergaard, Søren Dinesen, et al.
Publicado: (2021) -
Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine
por: Alhammad, Norah S, et al.
Publicado: (2022) -
Et de trois : l’UE recommande le vaccin AstraZeneca/Oxford
por: Manus, Jean-Marie
Publicado: (2021)